DE60130797D1 - Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose - Google Patents
Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenoseInfo
- Publication number
- DE60130797D1 DE60130797D1 DE60130797T DE60130797T DE60130797D1 DE 60130797 D1 DE60130797 D1 DE 60130797D1 DE 60130797 T DE60130797 T DE 60130797T DE 60130797 T DE60130797 T DE 60130797T DE 60130797 D1 DE60130797 D1 DE 60130797D1
- Authority
- DE
- Germany
- Prior art keywords
- stenosis
- antagonists
- treatment
- migration
- smooth muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22967900P | 2000-09-01 | 2000-09-01 | |
US229679P | 2000-09-01 | ||
US26551601P | 2001-01-31 | 2001-01-31 | |
US265516P | 2001-01-31 | ||
US940101 | 2001-08-27 | ||
US09/940,101 US20020119148A1 (en) | 2000-09-01 | 2001-08-27 | ErbB4 antagonists |
PCT/US2001/026984 WO2002018444A2 (en) | 2000-09-01 | 2001-08-29 | Erbb4 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60130797D1 true DE60130797D1 (de) | 2007-11-15 |
DE60130797T2 DE60130797T2 (de) | 2008-08-07 |
Family
ID=27397993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60130797T Expired - Lifetime DE60130797T2 (de) | 2000-09-01 | 2001-08-29 | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose |
Country Status (12)
Country | Link |
---|---|
US (6) | US20020119148A1 (de) |
EP (1) | EP1351744B1 (de) |
JP (1) | JP2004507559A (de) |
AT (1) | ATE374642T1 (de) |
AU (2) | AU2001286918B2 (de) |
CA (1) | CA2420062C (de) |
DE (1) | DE60130797T2 (de) |
DK (1) | DK1351744T3 (de) |
ES (1) | ES2295202T3 (de) |
HK (1) | HK1059404A1 (de) |
IL (2) | IL154495A0 (de) |
WO (1) | WO2002018444A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
WO2002098445A1 (en) * | 2001-05-30 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Protein preparation |
AU2003237367A1 (en) * | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
RU2338751C2 (ru) | 2002-07-15 | 2008-11-20 | Дженентек, Инк. | СПОСОБЫ ИДЕНТИФИКАЦИИ ОПУХОЛЕЙ, ВОСПРИИМЧИВЫХ К ЛЕЧЕНИЮ АНТИТЕЛАМИ ПРОТИВ ErbB2 |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
JP4527388B2 (ja) * | 2003-12-11 | 2010-08-18 | 東洋鋼鈑株式会社 | ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法 |
MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2006096663A2 (en) * | 2005-03-07 | 2006-09-14 | Targeted Molecular Diagnostics, Llc | Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease |
KR101598229B1 (ko) * | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Erbb3에 대한 항체 및 이의 용도 |
AU2009228058A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
KR20110044905A (ko) * | 2008-08-15 | 2011-05-02 | 메리맥 파마슈티컬즈, 인크. | 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템 |
CN109608545A (zh) | 2008-11-25 | 2019-04-12 | 健泰科生物技术公司 | 同等型特异性抗her4抗体 |
TWI461211B (zh) * | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
WO2011107100A1 (en) | 2010-03-03 | 2011-09-09 | Aarhus Universitet | Methods and compositions for regulation of herv4 |
BR112012022802A2 (pt) | 2010-03-11 | 2018-05-15 | Merrimack Pharmaceuticals Inc | uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama |
EP2640831A1 (de) | 2010-11-17 | 2013-09-25 | Sea Lane Biotechnologies,llc. | Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel |
SG10201606158TA (en) | 2011-08-05 | 2016-09-29 | Regeneron Pharma | Humanized universal light chain mice |
MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
PE20150956A1 (es) | 2012-11-08 | 2015-06-20 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3 |
CA2884429A1 (en) * | 2012-11-08 | 2014-05-15 | Birgit Bossenmaier | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
FR3020063A1 (fr) * | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
RU2016148682A (ru) | 2014-05-14 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3 |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2037440A1 (en) | 1990-03-02 | 1991-09-03 | Gregory D. Plowman | Her3: a novel egf receptor homolog |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
WO1996015128A2 (en) * | 1994-11-14 | 1996-05-23 | Warner-Lambert Company | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION |
US5770567A (en) * | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
JP4274581B2 (ja) * | 1996-07-12 | 2009-06-10 | ジェネンテック・インコーポレーテッド | キメラヘテロ多量体接着体 |
JP4382879B2 (ja) * | 1996-07-12 | 2009-12-16 | ジェネンテック・インコーポレーテッド | ガンマ―ヘレグリン |
DE69739673D1 (de) * | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
US6994856B1 (en) * | 1997-07-24 | 2006-02-07 | Genentech, Inc. | ErbB4 receptor-specific neuregulin related ligands and uses therefor |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
BR9915487A (pt) * | 1998-11-19 | 2001-07-31 | Warner Lambert Co | N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases |
ATE385504T1 (de) * | 2000-06-06 | 2008-02-15 | Bristol Myers Squibb Co | Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
-
2001
- 2001-08-27 US US09/940,101 patent/US20020119148A1/en not_active Abandoned
- 2001-08-29 EP EP01966399A patent/EP1351744B1/de not_active Expired - Lifetime
- 2001-08-29 ES ES01966399T patent/ES2295202T3/es not_active Expired - Lifetime
- 2001-08-29 AU AU2001286918A patent/AU2001286918B2/en not_active Ceased
- 2001-08-29 DE DE60130797T patent/DE60130797T2/de not_active Expired - Lifetime
- 2001-08-29 JP JP2002523958A patent/JP2004507559A/ja active Pending
- 2001-08-29 IL IL15449501A patent/IL154495A0/xx unknown
- 2001-08-29 AT AT01966399T patent/ATE374642T1/de active
- 2001-08-29 WO PCT/US2001/026984 patent/WO2002018444A2/en active IP Right Grant
- 2001-08-29 CA CA2420062A patent/CA2420062C/en not_active Expired - Fee Related
- 2001-08-29 AU AU8691801A patent/AU8691801A/xx active Pending
- 2001-08-29 US US10/362,380 patent/US7332579B2/en not_active Expired - Fee Related
- 2001-08-29 DK DK01966399T patent/DK1351744T3/da active
-
2003
- 2003-02-17 IL IL154495A patent/IL154495A/en not_active IP Right Cessation
-
2004
- 2004-03-27 HK HK04102271A patent/HK1059404A1/xx not_active IP Right Cessation
-
2005
- 2005-10-11 US US11/248,122 patent/US20060093603A1/en not_active Abandoned
-
2006
- 2006-10-13 US US11/581,221 patent/US20070092513A1/en not_active Abandoned
-
2008
- 2008-06-24 US US12/215,200 patent/US7704498B2/en not_active Expired - Fee Related
-
2010
- 2010-04-02 US US12/753,792 patent/US20100190964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002018444A2 (en) | 2002-03-07 |
AU2001286918B2 (en) | 2006-12-21 |
US20060093603A1 (en) | 2006-05-04 |
US20100190964A1 (en) | 2010-07-29 |
US20020119148A1 (en) | 2002-08-29 |
WO2002018444A3 (en) | 2003-07-31 |
US7332579B2 (en) | 2008-02-19 |
ES2295202T3 (es) | 2008-04-16 |
AU8691801A (en) | 2002-03-13 |
IL154495A0 (en) | 2003-09-17 |
DE60130797T2 (de) | 2008-08-07 |
JP2004507559A (ja) | 2004-03-11 |
CA2420062C (en) | 2014-04-01 |
EP1351744B1 (de) | 2007-10-03 |
US20090068205A1 (en) | 2009-03-12 |
US20040052786A1 (en) | 2004-03-18 |
HK1059404A1 (en) | 2004-07-02 |
CA2420062A1 (en) | 2002-03-07 |
ATE374642T1 (de) | 2007-10-15 |
US20070092513A1 (en) | 2007-04-26 |
IL154495A (en) | 2009-12-24 |
US7704498B2 (en) | 2010-04-27 |
DK1351744T3 (da) | 2008-02-11 |
EP1351744A2 (de) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE376446T1 (de) | Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
CY1107453T1 (el) | Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις | |
MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
DE60045474D1 (de) | Neues verfahren zum erschaffen von proteinkinase-inhibitoren | |
ATE552849T1 (de) | Behandlungsverfahren unter verwendung von ctla-4 antikörpern | |
DE69527847T2 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
DE69726724D1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
DE69915033D1 (de) | Verfahren zur keimungshemmende behandlung von knollen und zwiebeln mit eugenol und/oder isoeugenol | |
DE69519937T2 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
ATE267013T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
DE60236921D1 (de) | Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
MY141670A (en) | Material and method for treatment of timber | |
ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
DE602004004883D1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
DE69827387D1 (de) | Verwendung von pramipexol zur behandlung von restless-legs-syndrom | |
DE60239450D1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |